Nuclear and Near-Infrared (NIR) Imaging in Melanoma
Status:
Completed
Trial end date:
2014-10-01
Target enrollment:
Participant gender:
Summary
Objectives:
1. To determine the feasibility of using microdose amounts of near-infrared (NIR)
fluorescent contrast agent to image tumor-draining and contralateral lymphatics in
melanoma patients prior to standard-of-care sentinel lymph node biopsy OR completion
lymph node dissection (axillary or inguinofemoral)
2. To determine the feasibility of using nonradioactive optical imaging techniques with
indocyanine green (ICG) as a fluorescent contrast agent to characterize lymphatic
architecture and function by correlating the observed lymphatic structure and function
with tumor and nodal status as determined from standard-of-care immunohistochemical
evaluation.
Phase:
Phase 1
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborators:
National Cancer Institute (NCI) University of Texas